These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 34112711)

  • 1. Pyrotinib Treatment in Patients With HER2-positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data.
    Anwar M; Chen Q; Ouyang D; Wang S; Xie N; Ouyang Q; Fan P; Qian L; Chen G; Zhou E; Guo L; Gu X; Ding B; Yang X; Liu L; Deng C; Xiao Z; Li J; Wang Y; Zeng S; Hu J; Zhou W; Qiu B; Wang Z; Weng J; Liu M; Li Y; Tang T; Wang J; Zhang H; Dai B; Tang W; Wu T; Xiao M; Li X; Liu H; Li L; Yi W
    Clin Cancer Res; 2021 Aug; 27(16):4634-4641. PubMed ID: 34112711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of pyrotinib-based regimens in HER2 positive metastatic breast cancer: A retrospective real-world data study.
    Dai L; Gao T; Guo R; Chen Y; Wang J; Zhou S; Tang Y; Chen D; Huang S
    Neoplasia; 2024 Oct; 56():101029. PubMed ID: 39024777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis.
    Lin Y; Lin M; Zhang J; Wang B; Tao Z; Du Y; Zhang S; Cao J; Wang L; Hu X
    Cancer Res Treat; 2020 Oct; 52(4):1059-1066. PubMed ID: 32340083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term Outcome Analysis of Pyrotinib in Patients With HER2-Positive Metastatic Breast Cancer and Brain Metastasis: A Real-World Study.
    Liang X; Gui X; Yan Y; Di L; Liu X; Li H; Song G
    Oncologist; 2024 Feb; 29(2):e198-e205. PubMed ID: 37589217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice].
    Song GH; Li HP; DI LJ; Yan Y; Jiang HF; Xu L; Wan DG; Li Y; Wang MP; Xiao Y; Zhang RY; Ran R; Wang H
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):254-260. PubMed ID: 32306007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of pyrotinib-based therapy in patients with HER2-positive metastatic breast cancer: A real-world retrospective study.
    Li C; Bian X; Liu Z; Wang X; Song X; Zhao W; Liu Y; Yu Z
    Cancer Med; 2021 Dec; 10(23):8352-8364. PubMed ID: 34672424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and Safety of Pyrotinib-Based Therapy in the Treatment of HER2-Positive Breast Cancer Patients with Brain Metastases: A Multicenter Real-World Study.
    Huang J; Sun S; Tan Q; Zheng F; Zhou D; Man X; Hu Y; Li W; Song L; Zhang B; Xu L; Wang X; Xie X; Li H
    Clin Breast Cancer; 2024 Aug; 24(6):e509-e518.e1. PubMed ID: 38729821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyrotinib combined with metronomic etoposide in heavily pretreated HER2-positive metastatic breast cancer: a single-arm, phase II study.
    Liu J; He M; Jiang M; Zhou S; Zhang M; Li Y; Chen S; Cai R; Mo H; Lan B; Ma F; Xu B; Li Q
    BMC Cancer; 2024 Oct; 24(1):1290. PubMed ID: 39425028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Efficacy and Safety of Inetetamab and Pyrotinib in Combination with Vinorelbine for Second-line Therapy and Beyond in HER2-positive Metastatic Breast Cancer: A Single-institution Clinical Experience.
    Wu F; Chen M; Wang L; Li N; Wu X; Chen X; Hong Y; Li C; Lin L; Chen K; Huang W; Liu J
    Curr Cancer Drug Targets; 2024; 24(5):490-500. PubMed ID: 37916639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of first-line dual oral pyrotinib plus capetabine therapy in HER2-positive metastatic breast cancer: A real-world retrospective study.
    Dai S; Zhang Y; Tan X; Luo F; Yan X
    Cancer Med; 2024 Jun; 13(11):e7256. PubMed ID: 38808952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyrotinib treatment enhances the radiosensitivity in HER2-positive brain metastatic breast cancer patients.
    Tian W; Hao S; Wang L; Chen Y; Li Z; Luo D
    Anticancer Drugs; 2022 Jan; 33(1):e622-e627. PubMed ID: 34407046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world data of pyrotinib-based therapy for patients with brain metastases of HER2-positive advanced breast cancer: a single-center retrospective analysis and molecular portraits.
    Wang H; Liu Q; Zhang M; Zhang J; Ran R; Ma Y; Yang J; Wang F; He S; Zhao X; Wang L; Zhang L; Dong D; Yang J
    Front Oncol; 2023; 13():1105474. PubMed ID: 37397372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
    Ma F; Li Q; Chen S; Zhu W; Fan Y; Wang J; Luo Y; Xing P; Lan B; Li M; Yi Z; Cai R; Yuan P; Zhang P; Li Q; Xu B
    J Clin Oncol; 2017 Sep; 35(27):3105-3112. PubMed ID: 28498781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases.
    Ma X; Li Y; Li L; Gao C; Liu D; Li H; Zhao Z; Zhao B
    Ann Med; 2022 Dec; 54(1):3085-3095. PubMed ID: 36331291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pyrotinib combining with radiotherapy on breast cancer with brain metastasis.
    Ma X; Li Y; Zhao Z; Li L; Gao C; Liu D; Li B; Zhao B
    Exp Biol Med (Maywood); 2023 Jan; 248(2):106-116. PubMed ID: 36533572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival benefit and biomarker analysis of pyrotinib or pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer: a pooled analysis of two phase I studies.
    Guan X; Ma F; Li Q; Chen S; Lan B; Fan Y; Wang J; Luo Y; Cai R; Zhang P; Li Q; Xu B
    Biomark Res; 2023 Feb; 11(1):21. PubMed ID: 36803645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of pyrotinib in treating HER2-positive breast cancer patients with brain metastasis: A multicenter study.
    Gao M; Fu C; Li S; Chen F; Yang Y; Wang C; Qin J; Liu S; Zhang R; Wang C; Zong J; Meng L; Meng X
    Cancer Med; 2022 Feb; 11(3):735-742. PubMed ID: 34962098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial.
    Li Q; Guan X; Chen S; Yi Z; Lan B; Xing P; Fan Y; Wang J; Luo Y; Yuan P; Cai R; Zhang P; Li Q; Zhong D; Zhang Y; Zou J; Zhu X; Ma F; Xu B
    Clin Cancer Res; 2019 Sep; 25(17):5212-5220. PubMed ID: 31138588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of pyrotinib-containing regimen in the patients with HER2-positive metastatic breast cancer: A multicenter real-world study.
    Yin S; Chi Y; Du Y; Wang J; Shan C; Yi W; Shang M; Man X; Tan Q; Li H
    Cancer Med; 2023 Feb; 12(3):2333-2344. PubMed ID: 35894763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
    Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
    Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.